INTRODUCTION
============

According to the recently published guidelines for the treatment of head and neck cancer^[@ref1],\ [@ref2])^ all patients with T1-T2 laryngeal cancer should be treated, at least initially, with the intent of larynx preservation. The recommended strategies for early glottic cancer (GC) with the intent of larynx preservation are radiotherapy (RT), transoral laser surgery, and partial laryngectomy. Therefore, early stage GC is a good candidate for definitive RT. The 5-year local control (LC) rates for T1 GC treated with RT have been reported in the range 73.6--94% in the T1 larynx.^[@ref3]-[@ref12])^

At 10 institutions in the Tokai District, Japan,^[@ref8])^ the 5-year LC rates for T1a and T1b GCs treated with RT alone between 2000 and 2005 were reported to be 86.5% and 83.6%, respectively. These results were not consistent with those reported by other institutions.^[@ref3],\ [@ref7],\ [@ref9]-[@ref10])^ The 5-year LC rates reported by other institutions were more than 90% for T1a and T1b tumors. Definitive RT for T1 GC using a dose of ≥2.25 Gy per fraction has been reported to yield a higher response rate compared to 2 Gy per fraction. In addition, because of the increase in the number of patients who require radiotherapy treatment, reducing the treatment duration helps avoid delays in the administration of starting RT in new patients.^[@ref13]-[@ref14])^

We, the Tokai Study Group for Therapeutic Radiology and Oncology (TOSTRO), started definitive RT for T1 GC using a RT dose of 2.25 Gy per fraction in 2011. In our institute and others, we administered a hypofractionated RT dose of 2.25 Gy for T1 GC, and aimed for a better outcome without increasing adverse events in clinical practice.

In the present study, we reported the initial 5-year experience for the 10 institutes of TOSTRO.

PATIENTS AND METHODS
====================

TOSTRO administered a questionnaire survey concerning the administration of RT for T1 GC. This questionnaire is summarized in [Table 1](#table1){ref-type="table"}. This study was approved by the institutional review board of the Nagoya University Hospital, and after approval of the ethics committee of each participating institution, anonymized treatment information was collected in the form of a questionnaire. A retrospective analysis was performed on 104 eligible patients.

###### 

Questionnaire item

  ---- --------------------------------------------------------------------------
  1    Age, sex, and PS
  2    T-stage: T1a / T1b
  3    Tumor type: Exophytic / Superficial / Ulcerative
  4    Anterior commissure invasion; yes or no
  5    Tumor size: Is larger than two thirds of the vocal cord?
  6    Irradiation starting date, ending date, and break period
  7    X-ray beam energy, dose fractionation, and total radiation dose
  8    Primary response and local control
  9    Regional lymph node metastases; yes or no, distant metastases; yes or no
  10   Alive or dead, the date last verified
  11   Acute adverse effects, late adverse effects (CTCAE ver. 4.0)
  12   Secondary treatments
  13   Secondary cancer
  ---- --------------------------------------------------------------------------

ECOG, Eastern Cooperative Oncology Group; CTCAE: Common Terminology Criteria for Adverse Events; PS, Performance status

Patients aged \>20 years with T1 glottic squamous cell carcinoma who underwent RT alone were included in the analysis. Three-dimensional treatment planning was performed for all patients with patients placed in a supine position and immobilized with thermoplastic masks. A standard radiation dose of 63 Gy was administered in 28 fractions (2.25 Gy per fraction). The patients were treated using lateral opposed fields, and weighted beams and wedges were used as appropriate to improve dose homogeneity (field size, approximately 5 × 5 cm).

In a periodic follow-up, symptoms occurring in the interval between the initiation of RT and 90 days after this time point were classified as acute adverse effects. Late adverse events were defined as those appearing 3 months after the completion of the treatment. The evaluation of acute adverse events and late adverse events was performed using the Common Terminology Criteria for Adverse Events version 4.0.^[@ref15])^

RESULTS
=======

Data collected from 10 institutes of TOSTRO were analyzed. The results were summarized in Tables 2--5. In total, there were 98 men and 6 women subjects. The median age was 71 (44--88) years. Seventy-one patients were stage T1a (74%) and 28 patients (27%) had anterior commissure invasion. Sixty-two patients (60%) had exophytic and 35 patients (34%) had superficial tumor types. Sixty-three patients (61%) had localized lesions and 41 (39%) had extended lesions (≥2/3 in vocal cord length). The details of the analysis are demonstrated in [Table 2](#table2){ref-type="table"}.

###### 

Patient characteristics

  Characteristics                              No. of Patients (%)
  --------------------------------- ---------- ---------------------
  Sex                                          
  Men                               98 (94)    
  Female                            6 (6)      
  Age                                          
  Median                            71 y.o     
  Range                             44 -- 88   
  Performance status                           
  0                                 68 (65)    
  1                                 30 (29)    
  2                                 6 (6)      
  *Classification of tumor*                    
  T-stage                                      
  T1a                               71 (74)    
  T1b                               33 (26)    
  Anterior commissure invasion                 
  no                                76(73)     
  yes                               28 (27)    
  Tumor type                                   
  Exophytic                         62 (60)    
  Superficial                       35 (34)    
  Ulcerative                        7 (6)      
  Tumor size                                   
  localized (\<2/3 of vocal cord)   63 (61)    
  extended (≥2/3 of vocal cord)     41 (39)    

Treatment factors and outcomes are summarized in [Table 3](#table3){ref-type="table"}. Sixty-seven patients (64%) were treated using a 4 MV treatment beam and 37 (36%) patients were treated using a 6 MV treatment beam. The total dose range was 56.25--67.5 Gy and 96 patients (92%) received an RT dose of 63.0 Gy. The median follow-up period was 18 (3.7--49.5) months. Complete local response was achieved in 102 patients (98%) and 2 patients showed local recurrence. Acute grade 3 adverse events were observed in 10 patients; 7 with dermatitis (7%) and 3 with mucositis (3%) ([Table 4](#table4){ref-type="table"}). For the assessment of late adverse events, we evaluated the 85 patients who were followed up for more than half a year ([Table 5](#table5){ref-type="table"}). There were no late adverse effects above grade 3 at the time. Nine patients (11%) had overall treatment times ≥44 days owing to periods of infectious diseases in 2 patients and long holidays in 7 patients. The details of the 2 patients who experienced local recurrence are summarized in [Table 6](#table6){ref-type="table"}.

###### 

Treatment factors and possible outcomes

CR, Complete response; PR, Partial response; NC, No change

  *Treatment factors*             No. of Patients (%)   
  ------------------------------- --------------------- ------------
  Energy                                                
                                  4 MV                  67 (64)
                                  6 MV                  37 (36)
  Dose (Gy)                                             
                                  56.25                 5 (5)
                                  60.75                 1 (1)
                                  63.00                 96 (92)
                                  67.50                 1 (2)
  *Treatment outcome*                                   
  Response                                              
                                  CR                    102 (98)
                                  PR                    1 (1)
                                  NC                    0 (0)
                                  Unknown               1 (1)
  Local failure                                         
                                  Yes                   2 (2)
                                  No                    101 (97)
                                  Unknown               1 (1)
  Overall treatment time (days)                         
                                  Median                41
                                  Range                 33--50
  Follow-up (months)                                    
                                  Median                18
                                  Range                 3.7-- 49.5
  Status                                                
                                  Alive                 99 (95)
                                  Dead                  5 (5)
  Secondary cancer                                      
                                  Yes                   11 (11)
                                  No                    92 (88)
                                  Unknown               1 (1)

###### 

List of acute adverse events categorized according to the Common Terminology Criteria for Adverse Events ver. 4.0

  Acute adverse events     G0       G1       G2      G3   G4
  ------------------------ -------- -------- ------- ---- ----
  Dermatitis               0        73       24      7    0
                           \(70\)   \(23\)   \(7\)        
  Laryngeal mucositis      1        66       34      3    0
  \(1\)                    \(63\)   \(33\)   \(3\)        
  Laryngeal edema          48       53       3       0    0
  \(46\)                   \(51\)   \(3\)                 
  Laryngeal hemorrhage     100      4        0       0    0
  \(96\)                   \(4\)                          
  Pharyngolaryngeal pain   9        66       29      0    0
  \(9\)                    \(63\)   \(28\)                

###### 

Common Terminology Criteria for Adverse Events ver. 4.0

  Late adverse effects     G0       G1      G2   G3   G4
  ------------------------ -------- ------- ---- ---- ----
  Hoarseness               65       19      1    0    0
  \(63\)                   \(29\)   \(2\)             
  Laryngeal necrosis       85       0       0    0    0
  \(100\)                                             
  Laryngeal edema          68       17      0    0    0
  \(80\)                   \(20\)                     
  Laryngeal hemorrhage     85       0       0    0    0
  \(100\)                                             
  Pharyngolaryngeal pain   75       8       2    0    0
  \(88\)                   \(9\)    \(3\)             

###### 

Local recurrences

  No.   Gender/Age   PS   T     Tumor type                  Energy   Dose (Gy)   OTT (days)   Time of LF (Mo)   ST   Status
  ----- ------------ ---- ----- --------------------------- -------- ----------- ------------ ----------------- ---- -------------------------------
  1     Male / 88    0    T1b   Exophytic AC (+) extended   4 MV     63.0        43           4                 No   Alive with cancer at 8 months
  2     Male / 70    2    T1a   Superficial                 6 MV     56.25       44           16                No   Dead with HF in 20 Mo

PS, performance status; OTT, overall treatment time; AC, anterior commissure invasion; LF, local failure; Mo, months; LF, local failure; Mo, months; ST, salvage treatment, HF, heart failure

Secondary cancers were observed in 11 patients (11%) and no evidence of regional lymph node metastases and/or distant metastases were observed during the follow-up period.

DISCUSSION
==========

Laryngeal cancer is the most common cancer among the head and neck cancers. RT is an effective treatment method for early GC with the advantage of larynx preservation. The 5-year LC rates of stage T1 GCs treated with RT were approximately in the range 73.6--94%.^[@ref3]-[@ref12])^ The 5-year LC rates for stages T1a and T1b GCs treated with RT alone were previously reported by the 10 institutes in the TOSTRO group to be 86.5% and 83.8%, respectively.^[@ref8])^ A LC rate above 90% could not be achieved. In the retrospective analysis, definitive RT for stage T1 GC administered in ≥2.25 Gy fractions was previously reported to yield a higher response rate than that administered in 2 Gy fractions.^[@ref3],\ [@ref10])^ Moreover, recent randomized studies have shown an improvement in the LC rates of patients with stage T1 or T1a GC when the total planned radiation was delivered over a shorter overall treatment time using high-dose fractionation.^[@ref9],\ [@ref11])^ In addition, no significant differences were observed in the incidences of acute or late skin toxicities, mucous membrane, or larynx between the two treatment arms.

In the present study, we analyzed the accumulation results of the fractions that were modified from 2.0 Gy to 2.25 Gy in dose. 2 out of 104 patients showed recurrence. The details are summarized in [Table 6](#table6){ref-type="table"}. One of the patients was an elderly patient with a bulky stage T1 tumor that involved the anterior and posterior commissure. The primary effect was a partial response and the tumor was residual, but salvage operation could not be performed due to a very old man. The patient was still alive with cancer at the time of the study.

According to the report^[@ref12])^ that evaluated 208 stage T1 GC patients in a retrospective analysis, both the tumor bulk and anterior commissure involvement were significant factors for the LC rate in univariate analysis and tumor bulk was identified as the only significant factor for the LC rate in multivariate analysis. Although the benefits of hypofractionation have already been reported in a single-institution randomized trial for stage T1 GCs by Yamazaki *et al.*,^[@ref9])^ the multi-institutional randomized study conducted in Korea^[@ref11])^ could not statistically demonstrate the non-inferiority of the hypofractionation arm compared to the conventional fractionation arm. However, in a subgroup exploratory analysis of stage T1a disease, the 5-year local progression-free survival trended positively in the hypofractionation arm (76.7% vs. 93.0%; hazard ratio \[HR\], 3.65; p = 0.056). It was reported that they were unable to evaluate the effect of tumor bulk on the LC rate by hypofractionation.^[@ref11])^ We hypothesize that the LC rate of T1 with bulky or extended tumor is still inadequate, even if the dose has increased to 2.25 Gy.

The another local recurrent patient was superficial GC treated using a 6 MV treatment beam. His performance status was poor and he had many complications. The radiation dose administered was reduced to 56.25 Gy in 25 fractions. Nevertheless, the overall treatment time was prolonged. It was reported that the maintenance of the treatment was difficult. The treatment outcome in early GC patients who received primary irradiation using a 6 MV treatment beam is limited and controversial.^[@ref3],\ [@ref16]-[@ref19])^ From fundamental research^[@ref20])^ with Monte Carlo simulation of radiation treatment for GC with 6 MV parallel-opposed photon beams in the CT-based model of the neck, the significant underdosage at the air-tissue interface in the larynx occurs in traditional RT treatments, especially in the glottic part of the larynx.

We hypothesized this case had local recurrence because of the prolongation of the overall treatment time, less total dose, and underdosage of the tumor.

The present study was at its 5^th^ year of long-term follow-up at the time of the writing of the report and further long-term follow-up is required. If an increase in adverse events has not been observed and the improvement of LC compared to the 2 Gy has been likewise obtained, this treatment method is very useful and beneficial in clinical practice due to the reduction in the treatment period. Further investigation is recommended for its local control and the development of late adverse events.

In conclusion, the rates of acute adverse events in a multicenter survey for stage T1 GC patients treated with 2.25-Gy fractions were comparable to those in previous studies that used 2 Gy in fractions. The local control of GC appears to be good and we are gratified at the results. However, further investigation is required for its local control and late adverse events.
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